Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel + MK615 for unresectable or recurrent metastatic pancreatic cancer
jRCTs061180074Phase 2Completed
- Sponsor
- AdBio partners
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MK615, gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by AdBio partners. Primary endpoints: Safety and Disease control rate. Started May 2018; status: completed.
02
Drugs
MK615gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs061180074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180074.